- Home
- URGN vs CSV Comparison
URGN vs CSV Comparison
Compare URGN & CSV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- CSV
- Stock Information
- Founded
- URGN 2004
- CSV 1991
- Country
- URGN United States
- CSV United States
- Employees
- URGN N/A
- CSV 2420
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- CSV Other Consumer Services
- Sector
- URGN Health Care
- CSV Consumer Discretionary
- Exchange
- URGN Nasdaq
- CSV Nasdaq
- Market Cap
- URGN 904.0M
- CSV 670.2M
- IPO Year
- URGN 2017
- CSV 1996
- Fundamental
- Price
- URGN $18.79
- CSV $42.72
- Analyst Decision
- URGN Strong Buy
- CSV Strong Buy
- Analyst Count
- URGN 8
- CSV 3
- Target Price
- URGN $28.50
- CSV $58.67
- AVG Volume (30 Days)
- URGN 1.1M
- CSV 96.7K
- Earning Date
- URGN 11-05-2025
- CSV 10-29-2025
- Dividend Yield
- URGN N/A
- CSV 1.05%
- EPS Growth
- URGN N/A
- CSV 75.49
- EPS
- URGN N/A
- CSV 3.32
- Revenue
- URGN $94,238,000.00
- CSV $407,603,000.00
- Revenue This Year
- URGN $39.63
- CSV $3.82
- Revenue Next Year
- URGN $111.49
- CSV $2.27
- P/E Ratio
- URGN N/A
- CSV $12.87
- Revenue Growth
- URGN 10.85
- CSV 3.15
- 52 Week Low
- URGN $3.42
- CSV $30.15
- 52 Week High
- URGN $21.71
- CSV $49.41
- Technical
- Relative Strength Index (RSI)
- URGN 48.50
- CSV 41.20
- Support Level
- URGN $18.45
- CSV $41.38
- Resistance Level
- URGN $21.71
- CSV $43.89
- Average True Range (ATR)
- URGN 1.18
- CSV 0.98
- MACD
- URGN -0.18
- CSV -0.13
- Stochastic Oscillator
- URGN 17.51
- CSV 30.39
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About CSV Carriage Services Inc.
Carriage Services Inc is a provider of funeral and cemetery services and merchandise in the United States. It operates in two business segments: The Funeral Home Operations segment offers burial, cremation, and consultation services; removes and prepares remains; sells caskets, urns, and related funeral merchandise; and enables the use of funeral home facilities for visitation, remembrance, and transportation services. The Cemetery Operations segment provides services, such as mausoleum spaces and niches, private estates, lawn crypt gardens, traditional single burial gravesites, and burial vaults. The majority of revenue is derived from The Funeral Home Operations segment.